A Radiologist's Guide to the Changing Treatment Paradigm of Advanced Non–Small Cell Lung Cancer: The ASCO 2018 Molecular Testing Guidelines and Targeted Therapies

Chen, Lydia Y.; Smith, Daniel A.; Somarouthu, Bhanusupriya; Gupta, Amit; Gilani, Kambiz; Ramaiya, Nikhil H.

doi:10.2214/ajr.19.21135

Cited by 6 publications

(5 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The characteristics of the CPGs are summarized in Table 1. Seven CPGs were established for SCLC (10-16), 20 for NSCLC (17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36), and 22 for lung cancer regardless of histological subtype . The number of published CPGs increased every year, with a total of 22 CPGs published in 2020.…”

Section: Characteristics Of Selected Guidelinesmentioning

confidence: 99%

Evaluation of the reporting quality of clinical practice guidelines on lung cancer using the RIGHT checklist

Yang¹,

Lü²,

Ma³

et al. 2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background: In recent years, the number of clinical practice guidelines (CPGs) for lung cancer has increased, but the quality of these guidelines has not been systematically assessed so far. Our aim was to assess the reporting quality of CPGs on lung cancer published since 2018 using the International Reporting Items for Practice Guidelines in Health Care (RIGHT) instrument. Methods:We systematically searched the major electronic literature databases, guideline databases and medical society websites from January 2018 to November 2020 to identify all CPGs for small cell and nonsmall cell lung cancer (NSCLC). The search and extraction were completed using standardized forms.The quality of included guidelines was evaluated using the RIGHT statement. We present the results descriptively, including a stratification by selected determinants.Results: A total of 49 CPGs were included. The mean proportion across the guidelines of the 22 items of the RIGHT checklist that were appropriately reported was 57.9%. The items most common to be poorly reported were quality assurance (item 17) and description of the role of funders (item 18b), both of which were reported in only one guideline. The proportions of items within each of the seven domains of the RIGHT checklist that were correctly reported were Basic information 75.9%; background 83.2%; evidence 44.5%; recommendations 55.4%; review and quality assurance 12.2%; funding and declaration and management of interests 42.9%; and other information 38.1%. The reporting quality of guidelines did not differ between publication years. CPGs published in journals with impact factor >30 tended to be best reported. Conclusions:Our results revealed that reporting in CPGs for lung cancer is suboptimal. Particularly the declaration of funding and quality assurance are poorly reported in recent CPGs on lung cancer.

show abstract

Section: Characteristics Of Selected Guidelinesmentioning

confidence: 99%

Evaluation of the reporting quality of clinical practice guidelines on lung cancer using the RIGHT checklist

Yang¹,

Lü²,

Ma³

et al. 2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

“…They are used to remove the genes which have a strong correlation and nearly no correlation with sample labels. Corr (1) gi is the correlation between expression profiles of the ith gene and sample labels, and Corr (2) gi is the correlation between expression profiles of the ith gene and expression profiles of identified biomarkers. T is a constant used to search potential biomarkers, the correlation between potential biomarkers and identified biomarkers should be smaller than T .…”

Section: ) Feature Selectionmentioning

confidence: 99%

“…L UNG cancer is one of the most serious malignancies with the highest morbidity and mortality in the world currently. Non-small-cell lung cancer (NSCLC) accounts for 85% in all lung cancer cases, and also in all solid tumors, NSCLC makes up the largest proportion where tumors are caused by single-gene driver mutation [1]. Many biomarkers harboring driver mutations have been identified so far [2], including kirsten rat sarcoma viral oncogene homolog (KRAS), epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1) in NSCLC.…”

Section: Introductionmentioning

confidence: 99%

A Genotype-Based Ensemble Classifier System for Non-Small-Cell Lung Cancer

et al. 2020

View full text Add to dashboard Cite

The heterogeneity of cancer reflects the complexity of genetic mutations. Dissecting the heterogeneity plays an important role in the field of biomarker discovery, targeted therapy and drug designing. As it is time-consuming to identify new biomarkers in biological experiments, various machine learning methods have been developed. However, the current methods are limited because they ignore that patients may correspond to different disease-causing genotypes. In this article, a genotype-based ensemble classifier system (GECS) is proposed which aims to explain pathologies of NSCLC from the view of genotypes and identify the genetic subtypes of tumors. The core strategy of GECS is to construct multiple independent classifiers following the principle that one classifier is constructed based on one genotype of NSCLC. The analysis of synthetic data and three microarray datasets indicated that the proposed method outperforms existing approaches in the identification of genetic subtypes of tumors. The GECS method provides a useful tool for molecular pathology researches for dissecting the heterogeneity of cancer.

show abstract

“… Oncogene Drugs used in targeted therapies Estimated frequency in Lung ADC (%) Study Notable resistance patterns Reference EGFR Erlotinib, Afatinib, Gefitinib, Osimertinib, Dacomitinib, Osimertinib 15 FLAURA T790M mutation, rare transformation to small cell lung cancer 392 , 393 , 394 , 395 ALK Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib, Dabrafenib, Trametinib 5 ALEX, ALTA-1L, ASCEND-4 Mutations conferring to crizotinib (eg; L1196M and G1269A) 392 , 393 , 396 , 397 , 398 , 399 ROS1 Lorlatinib, Crizotinib, Ceritinib, Brigatinib 2 ALKA, STARTRK-1/2, PROFILE1001 Secondary ROS1 mutations, conferring resistance to crizotinib (e.g., G2032R, D2033N, and S1986F) [47] 44 , 393 , 400 , 401 , 402 BRAF Dabrafenib, Trametinib, Vemurafenib 2 NCT01336634 Resistance is common with monotherapy, but the mechanism is poorly understood. 392 , 393 , 403 RET Vandetanib, Sorafenib, Sunitinib, Cabozantinib 2 LIBRETTO-001, ARROW Not well understood 392 , 393 , 404 , 405 KRAS Trametinib, Selumetinib, Sotorasib In combination with other therapeutic agents 25–33 NCT03704688 Resistance commonly develops causing a decreased response to TKIs …”

Section: Introductionmentioning

confidence: 99%

Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics

Padinharayil

Varghese²,

John

et al. 2023

Genes & Diseases

View full text Add to dashboard Cite

A Radiologist's Guide to the Changing Treatment Paradigm of Advanced Non–Small Cell Lung Cancer: The ASCO 2018 Molecular Testing Guidelines and Targeted Therapies

Cited by 6 publications

References 59 publications

Evaluation of the reporting quality of clinical practice guidelines on lung cancer using the RIGHT checklist

Evaluation of the reporting quality of clinical practice guidelines on lung cancer using the RIGHT checklist

A Genotype-Based Ensemble Classifier System for Non-Small-Cell Lung Cancer

Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics

Contact Info

Product

Resources

About